IPO - CEL SCI CORP

Form Type: 424B5

Filing Date: 2025-03-18

Corporate Action: Ipo

Type: New

Accession Number: 000165495425002910

Filing Summary: CEL-SCI Corporation is offering 4,012,500 shares of common stock at a price of $0.16 per share and 11,987,500 Pre-Funded Warrants at $0.1599 each, intended for those whose stock purchase would exceed a 4.99% ownership threshold. This offering is part of a registration statement filed under Rule 424(b)(5) and has been designated under Registration No. 333-265995. The placement agent for the offering is ThinkEquity LLC, who will receive fees based on the total offerings. The delivery of securities is expected by March 18, 2025. CEL-SCI's common stock is traded on the NYSE American under the symbol 'CVM'. The company estimates net proceeds around $2.1 million after expenses, aimed at funding the development of Multikine and for general corporate purposes. The offering includes stipulations concerning market value and a lack of minimum offering conditions, leading to potentially reduced proceeds if not all securities are sold. Furthermore, in a significant clinical study, Multikine showed a promising survival advantage for patients with advanced primary head and neck cancer, supporting its potential role as a first-line immunotherapy treatment.

Document Link: View Document

Form Type: 424B5

Filing Date: 2024-12-27

Corporate Action: Ipo

Type: New

Accession Number: 000165495424015945

Filing Summary: CEL-SCI Corporation is conducting an offering of shares of common stock and Pre-Funded Warrants to purchase shares of common stock. This prospectus supplement, dated December 27, 2024, outlines the preliminary offering, which involves common stock priced at a specified rate, with a whole number of shares being offered to the public. Additionally, it includes pre-funded warrants issued to investors whose purchase would lead to ownership that exceeds regulatory thresholds. The prospectus discusses the expected uses of proceeds from the offering, indicating plans to finance the ongoing development of their lead investigational therapy, Multikine, which targets cancers of the head and neck. Current trials have shown promising results, with a significant survival advantage for patients receiving Multikine compared to those who do not. Furthermore, the document touches upon risks associated with the investment, the company's market strategies, and previous clinical research findings. The common stock is listed on the NYSE American under the symbol 'CVM.'

Document Link: View Document